Proactive Investors - Run By Investors For Investors

Imugene to present cancer vaccine research at AACR annual meeting

The company has multiple B-cell vaccine candidates aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies.
Imugene to present cancer vaccine research at AACR annual meeting
Imugene is a clinical stage immune-oncology company

Imugene Limited (ASX:IMU) scientific advisor Professor Ursula Wiedermann is to present on the company’s HER-Vaxx cancer vaccine at the American Association for Cancer Research (AACR) 2019 annual meeting.

Wiedermann is the co-inventor of HER-Vaxx and also a member of Imugene’s scientific advisory board.


The presentation is authored by Wiedermann and researchers at the Medical University of Vienna in Australia and Imugene.

Its title is ‘A phase1b open label multi-centre study with a HER2/neu peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy shows safety, immunogenicity and clinical response in patients with HER2/neu overexpressed advanced cancer of the stomach.

READ: Imugene targets defender B-cells with cancer vaccines HER-Vaxx and B-Vaxx

Imugene’s HER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours that over-express the HER2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.

The immunotheraphy is constructed from several B cell epitopes derived from the extracellular domain of HER2/neu.

It has been show in pre-clinical studies and phase-one studies to stimulate a potent polyclonal antibody response to HER2/neu, a well-known and validated cancer target.

READ: Imugene has cancer vaccine trial data published in prestigious medical journal

The company recently had its phase-one clinical trial data for its B cell cancer vaccine B-Vaxx published in the prestigious AACR journal Clinical Cancer Research.

The article was primarily authored by Imugene’s scientific advisory board members Professor Pravin Kaumaya from the Ohio State University and Dr Tanios Bekaii-Saab from the Mayo Clinic.

View full IMU profile View Profile

Imugene Ltd Timeline

Related Articles

Once the phase III trial is completed, Futura plans to either sell off the asset or find a partner
September 26 2018
The pharma group expects to dose the first patient in the Phase III trial of its MED2002 erectile dysfunction treatment within the next month
January 31 2019
Long-term fundamentals remain firmly in the seafood specialist's favour.
young girl with allergy
February 16 2019
Allergy Therapeutics is a long-established specialist in the prevention, diagnosis and treatment of allergies

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use